Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects

Open Access

Peer-reviewed

Research Article

Ingo Flamme ,

* E-mail: ingo.flamme@bayer.com

Affiliation Cardiology/Hematology, Acute Care Research, Global Drug Discovery, Bayer Pharma AG, Wuppertal, Germany
⨯
Felix Oehme,

Affiliation Biotech Development, Global Biologics, Bayer Pharma AG, Wuppertal, Germany
⨯
Peter Ellinghaus,

Affiliation Clinical Science, Global Biomarkers, Bayer Pharma AG, Wuppertal, Germany
⨯
Mario Jeske,

Affiliation Global Chemical Product Development, Bayer Pharma AG, Wuppertal, Germany
⨯
Jörg Keldenich,

Affiliation Drug Metabolism and Pharmacokinetics, Global Early Development, Bayer Pharma AG, Wuppertal, Germany
⨯
Uwe Thuss

Affiliation Drug Metabolism and Pharmacokinetics, Global Early Development, Bayer Pharma AG, Wuppertal, Germany
⨯

Reader Comments (0)

ACE inhibitor therapy
Is the Subject Area "ACE inhibitor therapy" applicable to this article?

Thanks for your feedback.
Kidneys
Is the Subject Area "Kidneys" applicable to this article?

Thanks for your feedback.
Anemia
Is the Subject Area "Anemia" applicable to this article?

Thanks for your feedback.
Blood pressure
Is the Subject Area "Blood pressure" applicable to this article?

Thanks for your feedback.
Chronic kidney disease
Is the Subject Area "Chronic kidney disease" applicable to this article?

Thanks for your feedback.
Blood plasma
Is the Subject Area "Blood plasma" applicable to this article?

Thanks for your feedback.
Hypoxia
Is the Subject Area "Hypoxia" applicable to this article?

Thanks for your feedback.
Gene expression
Is the Subject Area "Gene expression" applicable to this article?

Thanks for your feedback.